Circulating miRNA panels for specific and early detection in bladder cancer

• DOI: 10.1111/cas.13856
• Publication Date: 2018-11-01T09:16:22Z
• Authors: Wataru Usuba; Fumihiko Urabe; Yusuke Yamamoto; Juntaro Matsuzaki; Hideo Sasaki; Makiko Ichikawa; Satoko Takizawa; Yoshiaki Aoki; Shumpei Niida; Ken Kato; Shin Egawa; Tatsuya Chikaraishi; Hiroyuki Fujimoto; Takahiro Ochiya
• Keywords: Male; 0301 basic medicine; Gene Expression Profiling; Original Articles; Middle Aged; Sensitivity and Specificity; 3. Good health; Cohort Studies; Diagnosis, Differential; Gene Expression Regulation, Neoplastic; MicroRNAs; 03 medical and health sciences; Urinary Bladder Neoplasms; Biomarkers, Tumor; Humans; Female; Early Detection of Cancer; Aged

Bladder cancer is the 9th leading cause of death worldwide. The major problem in bladder primarily high recurrence rate after drug treatment and resection. Although conventional screening methods, such as cystoscopy, urinary cytology ultrasound sonography, have become widely used clinical settings, diagnostic performance these modalities unsatisfactory due to low accuracy or invasiveness. Because circulating micro RNA (miRNA) profiles recently been reported an attractive tool for liquid biopsy screening, here, we performed global miRNA profiling 392 serum samples patients with 100 non‐cancer 480 other types controls. We randomly classified control into 2 cohorts, a training set (N = 486) validation 486). By comparing both controls, identified specific miRNA, miR‐6087, diagnosing sets. Furthermore, found that combination 7 (7‐miRNA panel: miR‐6724‐5p, miR‐3960, miR‐1343‐5p, miR‐1185‐1‐3p, miR‐6831‐5p miR‐4695‐5p) could discriminate from tumors highest (AUC: .97; sensitivity: 95%; specificity: 87%). was high, regardless stage grade cancer. Our data demonstrated 7‐miRNA panel be biomarker early detection